CervoMed Inc. (CRVO) SEC Filings

CervoMed Inc. reported that Mark De Rosch, EVP, RA and GA and PgM, received an award of 19,100 stock options on October 22, 2026, covering 19,100 shares of common stock. The options have an exercise price of $2.24 per share and vest in 36 equal (or as near equal as possible) monthly installments on the last calendar day of each month, beginning October 31, 2026. They expire October 22, 2036.

CervoMed Inc.'s Chief Commercial and Business, Matthew Winton, received a direct stock-option award covering 19,100 common shares on October 22, 2026. The award vests in 36 equal (or as near equal as possible) monthly installments on each month's last calendar day, beginning October 31, 2026.

CervoMed Inc. (CRVO) made a presentation about its business, clinical studies, development plans, financial position and related matters available on its website under “Investors – Events and Presentations.” Company representatives may use the presentation, in whole or in part and possibly with non-material modifications, periodically at conferences, meetings and presentations to investors, analysts and others. CervoMed says it has no duty to publicly update or revise the presentation except as required by law.

CervoMed Inc. reported initial results from the first 12 weeks of its Phase 2a trial of neflamapimod in nonfluent variant primary progressive aphasia (nfvPPA): mean plasma neurofilament light chain (NfL) levels declined, with a greater decline among participants whose baseline levels were at or above the median. The trial also assessed glial fibrillary acidic protein (GFAP). The company described neflamapimod as generally well tolerated, with no new safety signals identified.

The 36-week study enrolled 25 participants and includes 24 weeks of open-label treatment, followed by a 12-week double-blind, placebo-controlled randomized withdrawal period. One patient with elevated liver enzyme levels met protocol-defined criteria for discontinuation; the patient was asymptomatic, had no associated bilirubin elevation, and the elevation resolved with treatment discontinuation. CervoMed expects to present 24-week biomarker data in November 2026 and clinical data in the first quarter of 2027.

CervoMed Inc. made information about its business, clinical studies, development plans and financial position available on its website under “Investors – Events and Presentations.” Company representatives may use the presentation periodically at conferences, meetings and presentations to investors, analysts and others, including with non-material modifications. The information is summary material intended to be considered alongside the company’s SEC filings and other public announcements.

CervoMed Inc. announced a new 50 mg neflamapimod tablet and said the FDA removed the prior plasma drug exposure limit, providing greater dosing flexibility in future clinical trials. The Phase 1 food-effect and drug-exposure study met its primary objectives. The tablet and prior 40 mg capsule produced similar overall plasma exposure after a single dose; the tablet’s profile showed approximately 20% lower Cmax and approximately 20% higher Ctrough 12 hours after dosing with twice-daily administration.

A 39-week dog toxicology study established a plasma-level-based NOAEL three-fold above prior dog studies and more than 30-fold above the pharmacologically and clinically active exposure range in earlier trials; the FDA removed the limit after reviewing these data. CervoMed plans to advance 100 mg twice daily in future trials. Modeling indicates this dose is expected to raise trough concentrations approximately 33% versus the 40 mg three-times-daily regimen used in Phase 2a and the Phase 2b extension.

CervoMed Inc. (CRVO) reported that it has posted an investor presentation on its website under the “Investors – Events and Presentations” section, which its representatives may use in periodic meetings and conferences. The information in this presentation is furnished, not filed, under a Regulation FD disclosure.

On September 10, 2026, the company announced that initial results from its Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia have been accepted as a late-breaking oral presentation at the Annual Meeting of the International Society of Frontotemporal Dementias, scheduled for October 8–11, 2026, in Philadelphia, Pennsylvania. The related press release is furnished as Exhibit 99.1.

RA Capital Management and affiliated funds report a significant ownership position in CervoMed Inc. As of June 30, 2026, RA Capital Healthcare Fund, L.P. directly holds warrants exercisable for up to 1,266,143 shares of CervoMed common stock. Based on 13,526,233 shares outstanding as of June 30, 2026 plus the warrant shares, the Reporting Persons collectively report beneficial ownership of 8.6% of the common stock. Voting and investment power over the Fund’s holdings have been delegated to RA Capital, and the Fund disclaims beneficial ownership for Section 13(d) purposes. RA Capital, Peter Kolchinsky, and Rajeev Shah may be deemed beneficial owners under Section 13(d) but disclaim beneficial ownership except for determining their reporting obligations.

CervoMed Inc. received an amended ownership report from CVI Investments, Inc. and Heights Capital Management, Inc. stating that they collectively hold 0 Shares of CervoMed common stock and 0.0% of the class as of the reported date. The entities report no sole or shared voting power and no sole or shared dispositive power over any CervoMed shares. Heights Capital Management, Inc. is described as investment manager to CVI Investments, Inc., and may be deemed beneficial owner of any shares held by CVI, although each reporting person disclaims beneficial ownership except for any pecuniary interest. The filing confirms ownership of 5 percent or less of the company’s common stock.